IAAG
EDIT icon

Innovative Asset Advisors Group’s Editas Medicine EDIT Stock Holding History

Innovative Asset Advisors Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-200
Closed -$494 – 499
2026
Q1 		$494 Buy
+200
New +$423 ﹤0.01% 990

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Innovative Asset Advisors Group's EDIT Position: Q2 2026 in Review

Innovative Asset Advisors Group sold out of Editas Medicine (EDIT) in Q2 2026, closing a stake of 200 shares — an estimated $494 sold.

Innovative Asset Advisors Group first reported a position in EDIT in Q1 2026 and held it in 1 quarter. The position peaked at $494 in Q1 2026. 199 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Innovative Asset Advisors Group reported no remaining Editas Medicine position as of Q2 2026 after selling out during the quarter.
  • Innovative Asset Advisors Group sold 200 Editas Medicine shares in Q2 2026, an estimated $494.
  • Innovative Asset Advisors Group first reported a position in Editas Medicine in Q1 2026 and held it in 1 quarter.
  • Innovative Asset Advisors Group's Editas Medicine position peaked at $494 in Q1 2026.
  • 199 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Innovative Asset Advisors Group's 13F filing for Q2 2026, filed 5 Aug 2026.